The CPTAC Symposium will begin on Wednesday, October 16 at 8:30 am and will conclude at 6:00 p.m.

**AGENDA**

8:00 a.m. - 8:30 a.m.  
*Registration*

8:30 a.m. - 8:40 a.m.  
*Opening Remarks*  
Douglas R. Lowy, M.D., Director (Acting)  
National Cancer Institute, NIH

8:40 a.m. - 9:00 a.m.  
*State of CPTAC (Status Report)*  
Henry Rodriguez, Ph.D., M.B.A.  
National Cancer Institute, NIH

9:00 a.m. - 10:30 a.m.  
**Session I**

9:00 a.m. - 9:30 a.m.  
*Deep Integrated Proteogenomic Characterization of Renal Cell Carcinoma*  
David Clark, Ph.D.  
Johns Hopkins University

9:30 a.m. - 10:00 a.m.  
*Proteogenomic Characterization of Endometrial Carcinoma*  
Emily Kawaler, M.S.  
New York University Langone Health

10:00 a.m. - 10:30 a.m.  
*Proteogenomic Analysis of Pediatric Brain Tumors and Adult Glioblastoma Multiforme (CPTAC partnership with the Gabriella Miller Kids First Pediatric Research Program)*  
Brian R. Rood, M.D.  
Children’s National Health System  
Li Ding, Ph.D.  
Washington University in St. Louis, School of Medicine

10:30 a.m. - 10:55 a.m.  
*Break (Group Picture)*

10:55 a.m. - 12:10 p.m.  
**Session II**
10:55 a.m. - 11:20 a.m.  Proteogenomic characterization of ovarian high-grade serous cancer implicates mitotic kinase and replication stress  
Karin Rodland, Ph.D.  
Pacific Northwest National Laboratory; Oregon Health & Science University

11:20 a.m. - 11:45 a.m.  Integrated Glycoproteomic Characterization of Human High-Grade Serous Ovarian Cancer  
Hui Zhang, M.S., Ph.D.  
Johns Hopkins School of Medicine

11:45 a.m. - 12:10 p.m.  Ovarian Cancer and Platinum Resistance for Clinical Trials  
Michael Birrer, M.D., Ph.D.  
University of Alabama Comprehensive Cancer Center

12:10 p.m. - 1:45 p.m.  Lunch (on your own) and poster viewing

1:45 p.m. - 3:25 p.m.  Session III

1:45 p.m. - 2:10 p.m.  Comprehensive Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities  
Bing Zhang, Ph.D.  
Baylor College of Medicine

2:10 p.m. - 2:35 p.m.  Comprehensive Proteogenomic Analysis of Human Lung Adenocarcinoma  
Michael A Gillette, M.D., Ph.D.  
Broad Institute of MIT and Harvard

2:35 p.m. - 3:00 p.m.  Breast Cancer Proteogenomics for Clinical Trials  
Matthew J. Ellis, M.B., BChir, BSc., PhD, FRCP  
Baylor College of Medicine

3:00 p.m. - 3:25 p.m.  Global and Phosphoproteomic Analysis to Kinase Inhibitor Treatment in Acute Myeloid Leukemia (partnership with BEAT AML Master Clinical Trial)  
Elie Traer M.D., Ph.D.  
Oregon Health & Science University

3:25 p.m.- 3:45 p.m.  Break

3:45 p.m. - 6:00 p.m.  Session IV

3:45 p.m. - 4:10 p.m.  Development of Fit-For-Purpose Targeted Mass Spec Proteomic Assays  
Amanda G. Paulovich, M.D., Ph.D.  
Fred Hutchinson Cancer Reserarch Center

4:10 p.m. - 4:35 p.m.  Towards Single Cell [Comprehensive] Proteomics  
Tao Liu, Ph.D., Pacific Northwest National Laboratory

4:35 p.m.- 6:00 p.m.  Live Demo Workshop - Data Access and Informatic Tools

4:35 p.m. - 5:15 p.m.  Session 1: Data Access  
Proteomics: Karen Ketchum, Ph.D., ESAC, Inc.  
Genomics: Sharon Gaheen, Leidos Biomed  
Imaging: Justin Kirby, Frederick National Laboratory for Cancer Research
5:15 p.m. - 6:00 p.m.  

Session 2: Data Analysis Tool

• Data and Interactive Network Visualization for Proteogenomic Data: Mt. Sina team
• Multi-omics data analysis tool (LinkedOmics): BCM team
• Database to visualize post-translational modifications in humans (PTMcosmos): WashU team